Radioiodine-refractory (RAI-R) thyroid cancer
Thyroid cancer that no longer takes up radioactive iodine, or keeps growing despite it. This is when kinase inhibitor pills come in.
Defined by absence of uptake on a diagnostic scan, progression within 12 months of treatment, or cumulative activity >22.2 GBq (600 mCi) without control. Affects ~5-15% of differentiated thyroid cancers, often with BRAF V600E or TERT promoter mutations. Median survival historically 3-5 years; lenvatinib, sorafenib, and genotype-directed drugs (RET, NTRK, BRAF) apply.
Pages like this
not linked directly; found by shared links- TrialHiLo
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialASTRA
Shares MAPK inhibitor redifferentiation → radioiodine, Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialIoN
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TrialESTIMABL2
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TermLow-risk differentiated thyroid cancer (ATA risk)
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TermThyroidectomy
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TermRadioiodine therapy (I-131)
Shares Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
- TermTheranostics
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.